Skip to content

Antibiotic Prophylaxis in Ragged Placental Membranes

Antibiotic Prophylaxis in Ragged Placental Membranes: A Prospective, Multicenter, Randomized Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03459599
Enrollment
716
Registered
2018-03-09
Start date
2016-10-01
Completion date
2017-08-01
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometritis Postpartum, Endometritis, Membranes; Retained

Keywords

Antibiotic, Endometritis, Placental membranes, Prophylaxis, Ragged membranes

Brief summary

In some centres, women are routinely given a course of antibiotics postnatally if ragged placental membranes were present at delivery. The investigators examined the necessity such an intervention.

Detailed description

Postpartum endometritis resulting in sepsis remain one of the leading cause of maternal mortality in developing countries. Ragged placental membrane is a risk factor for endometritis and is not infrequently encountered. Several hospitals in Malaysia, largely those geographically-removed currently practice administering prophylactic antibiotics for women with ragged placental membranes. The aim is to reduce the risk of postpartum endometritis in a subgroup of women who may present in dire straits. The investigators sought to examine the necessity of such protocols.

Interventions

Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week

OTHERNo prophylaxis (Amox-clav withheld)

Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients

Sponsors

University Malaysia Sarawak
CollaboratorOTHER
Sarawak General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

All women who delivered vaginally beyond 24+0 weeks of gestation and were found to have ragged or retained placental membranes immediately after the third stage of labour were invited to participate in the study.

Exclusion criteria

1. Fever, within 5 days preceding delivery (Axillary temperature \> 37.5oC on 2 or more occasions at least 1 hour apart or temperature \> 38oC on one occasion). This also includes intrapartum fever. 2. Required oral or intravenous antibiotics for any other obstetric-related (ex. third or fourth degree tears, preterm prelabour rupture of membranes) or non- obstetric related (ex. pneumonia, acute pyelonephritis) reasons 3. Prolonged rupture of membrane (\>18 hours) 4. Retroviral disease, on long term oral or parenteral steroid or receiving other forms of immunosuppressants, including chemotherapy within the last one year. 5. Vaginal delivery for an intrauterine death 6. Penicillin allergy

Design outcomes

Primary

MeasureTime frameDescription
Incidence of postpartum endometritis6 weeks postpartumPostpartum endometritis is defined as follows, when presenting anytime within 6 weeks postpartum 1. Fever (Axillary temperature \> 37.5 degrees Celcius on 2 or more occasions at least 1 hour apart or temperature \> 38 degrees Celcius on one occasion), occurring in the absence of apparent source of infection or alternative foci of infection. 2. Increasing lochia loss or offensive lochia. 3. Lower abdominal pain or suprapubic tenderness on palpation. The diagnosis is further supported by the following: 1. Elevated total white cell count \> 11.0 x 109 cells/L 2. Positive genital swab culture. Incidence is calculated as follows: Number of patients diagnosed with endometritis in each arm/total number of patients allocated to each arm

Secondary

MeasureTime frameDescription
ICU admission rate6 weeks postpartumICU admission as a result of endometritis. It is measured as follows: a. ICU admission rate in prophylactic antibiotic group= (Number of patients requiring ICU admissions and given antibiotic prophylaxis, regardless of duration/total number of patients given antibiotics prophylaxis ) a. ICU admission rate in no prophylaxis group = (Number of patients requiring ICU admissions and NOT given antibiotic prophylaxis, regardless of duration/total number of patients NOT given antibiotics prophylaxis)
Rate of surgical evacuation of retained products of conception6 weeks postpartumSurgical procedure required as a result of ragged placental membrane or its complications. It is calculated as follows 1. Surgical evacuation of retained products of conception in prophylaxis group= (Number of patients requiring surgical procedure and given antibiotic prophylaxis, regardless of duration/total number of patients given antibiotics prophylaxis ) 2. Surgical evacuation of retained products of conception in no prophylaxis group= (Number of patients requiring surgical procedure and NOT given antibiotic prophylaxis, regardless of duration/total number of patients NOT given antibiotics prophylaxis )
Rate of Blood transfusion6 weeks postpartumPack cell transfusion required as secondary to a complication from ragged placental membranes. This can be due to postpartum endometritis or surgical evacuation. It is calculated based on the number of patients requiring transfusion. The number of pack cells required per patient would be also be described. 1. Blood transfusion in prophylaxis group= (Number of patients requiring pack cell transfusion and given antibiotic prophylaxis, regardless of duration/total number of patients given antibiotics prophylaxis ) 2. Blood transfusion in no prophylaxis group= (Number of patients requiring pack cell transfusion and were NOT given antibiotic prophylaxis, regardless of duration/total number of patients NOT given antibiotics prophylaxis )

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026